FABINO ENTERPRISES LIMITED Share Price
FABINO ENTERPRISES LIMITED Returns Calculator
FABINO ENTERPRISES LIMITED Shareholder Returns
FABINO ENTERPRISES LIMITED Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
FABINO ENTERPRISES LIMITED Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Revenue | ₹18.04 | ₹21.08 | ₹3.36 |
| Other Income | ₹0.29 | ₹0.01 | ₹0.02 |
| Total Revenue | ₹18.33 | ₹21.09 | ₹3.38 |
| Total Expenses | ₹18.14 | ₹21.04 | ₹3.37 |
| Profit Before Tax | ₹0.19 | ₹0.05 | ₹0.01 |
| Tax | ₹0.13 | ₹0.01 | ₹0.00 |
| Profit After Tax | ₹0.06 | ₹0.04 | ₹0.01 |
| EPS - Basic | ₹0.29 | ₹0.17 | ₹0.05 |
| EPS - Diluted | ₹0.29 | ₹0.17 | ₹0.05 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Profit before tax | ₹0.19 | ₹0.04 | ₹0.01 |
| Income before WC changes | ₹0.40 | ₹0.13 | ₹0.05 |
| Change in Assets | -₹1.91 | -₹10.33 | -₹0.76 |
| Change in Liabilities | ₹1.76 | ₹9.44 | ₹0.04 |
| Change in WC | -₹0.15 | -₹0.89 | -₹0.71 |
| Cash flow from Operations | ₹0.12 | -₹0.77 | -₹0.68 |
| Cash flow from Investing | -₹0.42 | -₹0.28 | -₹0.01 |
| Cash flow from Financing | ₹0.48 | ₹0.86 | ₹0.34 |
| Total Cash Flow | ₹0.18 | -₹0.18 | -₹0.35 |
| Cash (Start of the year) | ₹0.06 | ₹0.24 | ₹0.59 |
| Cash (End of the year) | ₹0.24 | ₹0.06 | ₹0.24 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Non-Current Assets | ₹0.62 | ₹0.43 | ₹0.23 |
| Current Assets | ₹17.03 | ₹14.93 | ₹4.78 |
| Total Assets | ₹17.66 | ₹15.36 | ₹5.01 |
| Current Liabilities | ₹11.66 | ₹9.90 | ₹0.45 |
| Net Current Asset | ₹5.37 | ₹5.03 | ₹4.33 |
| Non-Current Liabilities | ₹1.79 | ₹1.31 | ₹0.45 |
| Equity Capital | ₹4.20 | ₹4.14 | ₹4.11 |
| Total Equity & Liabilities | ₹17.66 | ₹15.36 | ₹5.01 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹18.04 | ₹6.08 | ₹3.36 | ₹4.20 |
| Other Income | ₹0.29 | ₹0.29 | ₹0.02 | ₹0.01 |
| Total Revenue | ₹18.32 | ₹6.38 | ₹3.38 | ₹4.21 |
| Total Expenses | ₹18.07 | ₹6.32 | ₹3.37 | ₹4.15 |
| Profit Before Tax | ₹0.26 | ₹0.06 | ₹0.01 | ₹0.07 |
| Tax | ₹0.13 | ₹0.02 | ₹0.00 | ₹0.02 |
| Profit After Tax | ₹0.13 | ₹0.05 | ₹0.01 | ₹0.05 |
| EPS - Basic | ₹0.63 | ₹0.23 | ₹0.05 | ₹0.22 |
| EPS - Diluted | ₹0.63 | ₹0.23 | ₹0.05 | ₹0.22 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹0.26 | ₹0.05 | ₹0.01 | ₹0.05 |
| Income before WC changes | ₹0.45 | ₹0.11 | ₹0.05 | ₹0.10 |
| Change in Assets | -₹3.09 | -₹7.10 | -₹0.76 | -₹1.84 |
| Change in Liabilities | ₹2.64 | ₹4.02 | ₹0.04 | -₹0.16 |
| Change in WC | -₹0.45 | -₹3.08 | -₹0.71 | -₹2.00 |
| Cash flow from Operations | -₹0.12 | -₹2.99 | -₹0.68 | -₹1.90 |
| Cash flow from Investing | -₹0.41 | -₹0.18 | -₹0.01 | -₹0.05 |
| Cash flow from Financing | ₹0.73 | ₹0.43 | ₹0.34 | ₹2.47 |
| Total Cash Flow | ₹0.20 | -₹2.75 | -₹0.35 | ₹0.52 |
| Cash (Start of the year) | -₹2.50 | ₹0.24 | ₹0.59 | ₹0.07 |
| Cash (End of the year) | ₹0.22 | -₹2.50 | ₹0.24 | ₹0.59 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹0.59 | ₹0.37 | ₹0.23 | ₹0.27 |
| Current Assets | ₹12.42 | ₹9.13 | ₹4.78 | ₹4.36 |
| Total Assets | ₹13.01 | ₹9.50 | ₹5.01 | ₹4.62 |
| Current Liabilities | ₹7.11 | ₹4.46 | ₹0.45 | ₹0.41 |
| Net Current Asset | ₹5.32 | ₹4.66 | ₹4.33 | ₹3.95 |
| Non-Current Liabilities | ₹1.61 | ₹0.88 | ₹0.45 | ₹0.11 |
| Equity Capital | ₹4.29 | ₹4.16 | ₹4.11 | ₹4.10 |
| Total Equity & Liabilities | ₹13.01 | ₹9.50 | ₹5.01 | ₹4.62 |
About FABINO ENTERPRISES LIMITED
Fabino Enterprises Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing, marketing, trading and packaging of pharmaceutical and other wellness-focused consumer products. Its core business is the marketing of pharmaceutical formulations and products in the domestic market through its own distribution network and sales force under its own brand name, getting its ayurvedic formulations manufactured through loan licensing facilities, packing, and labeling. It exports wellness and fast-moving consumer goods (FMCG) products, such as coffee, malt powder, protein powder, hair shampoo, which are marketed by its company. Its products include 21 No Tea, AMOXRAG-625, Astrid Syrup, Aur D3 Capsules, Aurceta AM, Aurcis-Forte, Aurifox OZ, Aurimor Gold, Aurimor plus, Aurirug 200, Aurirug O, Aurnim Plus, Aurstin 250, Aurstin 500, Aurzyme-Syrup, Ayush Kadha, Calogrip, Cefga 1gm, Cekal Forte, Ceporag O, Coptec Capsules, Coptec-syrup, Cough-Free, and Dexrog Syrup.
FABINO ENTERPRISES LIMITED Financial Highlights
- Revenue: FABINO ENTERPRISES LIMITED reported revenue of ₹22.40 crore in FY26 vs ₹18.33 crore in FY25. It showed an increase of 22.20% on a yearly basis.
- Operating Profit: FABINO ENTERPRISES LIMITED reported an operating loss of ₹0.74 crore in FY26 vs ₹0.19 crore in FY25. It showed a decrease of 489.47% on a year-on-year basis.
- Net Profit: FABINO ENTERPRISES LIMITED reported a net loss of ₹0.56 crore in FY26 vs ₹0.06 crore in FY25. It showed a decrease of 1,033.33% on a yearly basis.
Similar Stocks
FAQs on FABINO ENTERPRISES LIMITED Share Price
What is FABINO ENTERPRISES LIMITED share price today?
FABINO ENTERPRISES LIMITED share price is ₹20.31 as on 27 Apr, 2026, 12:34 IST.
How much is the Mutual Fund shareholding in FABINO ENTERPRISES LIMITED shares?
The Mutual Fund Shareholding in FABINO ENTERPRISES LIMITED was 0.00% at the end of Mar 2026.
What is the the 52-week high and low of FABINO ENTERPRISES LIMITED shares ?
The 52-week high and low of FABINO ENTERPRISES LIMITED share is ₹29.26 and ₹13.01 as of 27 Apr, 2026.
What is the market cap of FABINO ENTERPRISES LIMITED?
The market capitalisation of FABINO ENTERPRISES LIMITED is ₹5.15 Crores as on 27 Apr, 2026.
What are the stock symbols of FABINO ENTERPRISES LIMITED?
The stock symbol of FABINO ENTERPRISES LIMITED is 543444 on the BSE, and the ISIN is INE0DRT01018.
How to buy FABINO ENTERPRISES LIMITED shares?
To buy FABINO ENTERPRISES LIMITED shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
What was yesterday's closing price for FABINO ENTERPRISES LIMITED shares ?
FABINO ENTERPRISES LIMITED shares closed yesterday at ₹20.31 on BSE
Can I buy FABINO ENTERPRISES LIMITED shares on Holidays?
No, shares of FABINO ENTERPRISES LIMITED or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell FABINO ENTERPRISES LIMITED shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.